Document is current

Article History

Accepted: 1 December 2024

First Online: 12 January 2025

Declarations

:

: No funding was received for this article.

: Dr. Kantrowitz is on the editorial board for CNS Drugs, and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Dr. Kantrowitz has received consulting payments within the last 36 months from Alphasights, CME Outfitters, Evoke, S.R. One, techspert.io, Health Monitor, minds+assembly, Third Bridge, MEDACorp, Marketplus, minds+assembly, FCB Health, Trinity, Globaldata, GKA, Clearview, Clarivate, Health Advances, ECRI Institute, ExpertConnect, Slingshot, Antheum, Guidepoint, First Thought, Wedbush, VMLY&R, Bluestar BioAdvisors, Jefferies, Reckner, Medscape, VoxNeuro, and Otsuka. He has served on the Medincell, Merck, Leal, and Karuna Advisory Boards in the past 36 months. He has conducted clinical research supported by the NIMH, Sunovion, Roche, Click, Neurocrine, Alkermes, Alto, Taisho, and Boehringer Ingelheim within the last 36 months. He owns a small number of shares of common stock from GSK. Ms. Govil reports no conflicts.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Dr. Kantrowitz and Ms. Govil completed the literature search and wrote the first and subsequent drafts of this review. All authors have read and approved the final submitted manuscript, and agree to be accountable for the work.